Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration

BACKGROUND: Optimal integration of induction chemoimmunotherapy with definitive chemoradiotherapy (CRT) and maintenance immunotherapy for unresectable stage III NSCLC remains undefined. METHODS: This multicenter retrospective study included 321 patients who received induction chemoimmunotherapy followed by CRT with or without maintenance immune checkpoint inhibitors (ICIs). Landmark survival from radiotherapy completion was used to avoid guarantee-time bias. RESULTS: Patients receiving 1-2 induction cycles showed numerically longer median PFS (28.0 months) than those with 3-4 (24.6) or >4 cycles (14.2; log-rank p = 0.179), but this trend was confounded by higher concurrent CRT rates in the 1-2 cycle group (74.5%vs. 47.1% vs. 33.7%). After propensity-score matching, the response-related survival advantage was attenuated (HR for PFS 0.70, p = 0.079). In matched analyses, maintenance ICI was associated with improved PFS (25.2 vs. 8.9 months; HR 0.47) and OS (NR vs. 22.0 months; HR 0.24) (both p < 0.001). An exploratory data-driven analysis suggested that >9 maintenance cycles yielded further PFS (HR 0.23) and OS (HR 0.17) benefits. CONCLUSION: In this real-world cohort, induction cycle number did not significantly affect survival; the apparent advantage of 1-2 cycles was likely confounded. Early radiographic response was not an independent predictor after matching. Maintenance ICI was associated with improved outcomes, and >9 cycles showed additional benefit, though with potential bias. These findings provide hypotheses for prospective trial design.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-13
DOI
https://doi.org/10.1016/j.tranon.2026.103113
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration

Hao Zhou, Liangxue Hou, Zewen Song, Yong Shi et al.
5 links
Translational Oncology
Lung Cancer Diagnosis and Treatment
article

Survival predictors in unresectable stage III NSCLC treated with induction chemoimmunotherapy: a real-world multicenter study of treatment cycles, response, and maintenance duration

Hao Zhou, Liangxue Hou, Zewen Song, Yong Shi, Wenyan Pan, Xuanyan Hu, Chaoyuan Liu, Yaoxiong Xia, Hao Hu, Yun Xiang Qi, Wei Bai, Pan Xi
article en

Abstract

BACKGROUND: Optimal integration of induction chemoimmunotherapy with definitive chemoradiotherapy (CRT) and maintenance immunotherapy for unresectable stage III NSCLC remains undefined. METHODS: This multicenter retrospective study included 321 patients who received induction chemoimmunotherapy followed by CRT with or without maintenance immune checkpoint inhibitors (ICIs). Landmark survival from radiotherapy completion was used to avoid guarantee-time bias. RESULTS: Patients receiving 1-2 induction cycles showed numerically longer median PFS (28.0 months) than those with 3-4 (24.6) or >4 cycles (14.2; log-rank p = 0.179), but this trend was confounded by higher concurrent CRT rates in the 1-2 cycle group (74.5%vs. 47.1% vs. 33.7%). After propensity-score matching, the response-related survival advantage was attenuated (HR for PFS 0.70, p = 0.079). In matched analyses, maintenance ICI was associated with improved PFS (25.2 vs. 8.9 months; HR 0.47) and OS (NR vs. 22.0 months; HR 0.24) (both p < 0.001). An exploratory data-driven analysis suggested that >9 maintenance cycles yielded further PFS (HR 0.23) and OS (HR 0.17) benefits. CONCLUSION: In this real-world cohort, induction cycle number did not significantly affect survival; the apparent advantage of 1-2 cycles was likely confounded. Early radiographic response was not an independent predictor after matching. Maintenance ICI was associated with improved outcomes, and >9 cycles showed additional benefit, though with potential bias. These findings provide hypotheses for prospective trial design.

Translational OncologyVol. 75
Central South University (CN), Jishou University (CN), University of Electronic Science and Technology of China (CN), Shanxi Medical University (CN), Kunming Medical University (CN), Shanxi Provincial Cancer Hospital (CN), Shangqiu First People's Hospital (CN), Sichuan Cancer Hospital (CN), Ningxia Medical University (CN), Ningxia Medical University General Hospital (CN), Second Xiangya Hospital of Central South University (CN), Third Xiangya Hospital (CN), Shanxi Provincial People’s Hospital (CN), Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital (CN)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon